Aytu BioPharma (NASDAQ:AYTU) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research cut shares of Aytu BioPharma (NASDAQ:AYTU) from a hold rating to a strong sell rating in a report released on Wednesday,Zacks.com reports.

Other research analysts also recently issued reports about the stock. Ascendiant Capital Markets increased their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research note on Thursday, June 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.75.

Aytu BioPharma Stock Performance

Shares of AYTU opened at $2.16 on Wednesday. The business’s 50 day moving average is $2.20 and its two-hundred day moving average is $2.44. Aytu BioPharma has a 52-week low of $1.65 and a 52-week high of $3.07. The firm has a market cap of $23.18 million, a price-to-earnings ratio of -0.47 and a beta of 0.24. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The business had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million. Analysts forecast that Aytu BioPharma will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP grew its holdings in Aytu BioPharma by 23.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after buying an additional 8,222 shares in the last quarter. Daytona Street Capital LLC acquired a new position in Aytu BioPharma during the 4th quarter worth $26,000. Persistent Asset Partners Ltd grew its stake in shares of Aytu BioPharma by 27.2% in the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares in the last quarter. Rothschild Wealth LLC bought a new position in shares of Aytu BioPharma in the fourth quarter worth $52,000. Finally, Bellevue Asset Management LLC bought a new position in shares of Aytu BioPharma in the fourth quarter worth $65,000. 33.49% of the stock is owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.